Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
Presented by Marcie Beasley, FNP-C, AOCNP®, and Brooke Daniel, MD
From Tennessee Oncology/OneOncology, Nashville, Tennessee
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2023;14(3):248–251 |
© 2023 Harborside™
HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. It is a clinically aggressive subtype; however, the introduction of targeted therapies has greatly improved survival rates. At JADPRO Live 2022, presenters discussed recent updates to clinical practice for HER2-positive metastatic breast cancer, and how to interpret emerging evidence on HER2-low data. They also highlighted best practices for monitoring and managing side effects for patients on these therapies.
For access to the full length article, please sign in